TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27422283

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Training and support
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Financial reimbursement
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Opportunity to refer patients to an internet-based brief intervention (e-BI)
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Paired combinations of strategies
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: All three strategies combined
Number of subjects: 746
Study: 23263261

Group type: EXPERIMENTAL
Intervention: Supervised medical exercise therapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 70
Study: 22976739

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (3 days/week, 50 min/day for 12 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (physical education activities)
Number of subjects: 22
Study: 21309475

Group type: EXPERIMENTAL
Intervention: Esomeprazole (20 mg/day) in healthy subjects
Number of subjects: 104

Group type: COMPARATOR
Intervention: Clopidogrel plus aspirin
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Esomeprazole (20 mg/day) in patients with a stent
Number of subjects: 104
Study: 17274713

Group type: EXPERIMENTAL
Intervention: 4% articaine HCl with 1:100,000 epinephrine (A100)
Number of subjects: 42

Group type: COMPARATOR
Intervention: 4% articaine HCl with 1:200,000 epinephrine (A200)
Number of subjects: 42
Study: 16171434

Group type: EXPERIMENTAL
Intervention: CHX (0.12% chlorhexidine digluconate)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CHX + 0.05% sodium fluoride (CHXNaF)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CHX + 0.05% cetylpyridinium chloride (CHX-CPC)
Number of subjects: 30
Study: 12736845

Group type: EXPERIMENTAL
Intervention: Women (n=24)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Men (n=11)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Office assistants (n=6 women)
Number of subjects: 35
Study: 10539831

Group type: EXPERIMENTAL
Intervention: 600 mg/d tranilast
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: 300 mg/d tranilast
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 8557899

Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg once daily)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg twice daily)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Combination therapy (metoprolol + nifedipine)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Nifedipine added to metoprolol
Number of subjects: 280

Group type: COMPARATOR
Intervention: Metoprolol added to nifedipine
Number of subjects: 280
Study: 1817760

Group type: EXPERIMENTAL
Intervention: Gallopamil sustained release (SR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6285406

Group type: EXPERIMENTAL
Intervention: 1 mg/kg CBD
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg delta 9‐THC
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Mixture of 0.5 mg/kg delta 9‐THC and 1 mg/kg CBD
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: COMPARATOR
Intervention: 10 mg diazepam
Number of subjects: 8
Study: 30176872

Group type: EXPERIMENTAL
Intervention: Nintedanib with anti-acid medication
Number of subjects: 1061

Group type: EXPERIMENTAL
Intervention: Nintedanib without anti-acid medication
Number of subjects: 1061

Group type: COMPARATOR
Intervention: Placebo with anti-acid medication
Number of subjects: 1061

Group type: COMPARATOR
Intervention: Placebo without anti-acid medication
Number of subjects: 1061
Study: 27160359

Group type: EXPERIMENTAL
Intervention: Everolimus (EVR)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Calcineurin inhibitor (CNI)
Number of subjects: 81
Study: 24830749

Group type: EXPERIMENTAL
Intervention: Daily Co-trimoxazole (CTX)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Sulfadoxine‐pyrimethamine (SP)
Number of subjects: 346
Study: 22354934

Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy
Number of subjects: 2179

Group type: COMPARATOR
Intervention: Heparin plus a GPI
Number of subjects: 2179

Group type: EXPERIMENTAL
Intervention: Baseline troponin elevation
Number of subjects: 2179
Study: 20156053

Group type: EXPERIMENTAL
Intervention: Physiotherapy exercise group (EG) - short-term supervised inpatient physiotherapy exercise protocol including early mobilisation with progressive exercises plus usual care (respiratory exercises)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Physiotherapy usual care group (UCG) - only received respiratory exercises
Number of subjects: 74
Study: 18754530

Group type: EXPERIMENTAL
Intervention: Myasthenic subjects
Number of subjects: 32

Group type: COMPARATOR
Intervention: Non-Myasthenic subjects
Number of subjects: 32
Study: 15939311

Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 microg once daily (o.d.)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ciclesonide 640 microg once daily (o.d.)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ciclesonide 640 microg twice daily (b.i.d.)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 440 microg twice daily (b.i.d.)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 880 microg twice daily (b.i.d.)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 14568851

Group type: EXPERIMENTAL
Intervention: Nerve growth factor treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional topical treatment
Number of subjects: 36
Study: 10930151

Group type: EXPERIMENTAL
Intervention: ALVAC‐HIV followed by the protein vaccine
Number of subjects: 0
Study: 8653191

Group type: EXPERIMENTAL
Intervention: Cost recovery intervention with improved drug supply in Say and Boboye
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control site (Illela)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Cost recovery intervention in Say
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Cost recovery intervention in Boboye
Number of subjects: 3
Study: 1900335

Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (GTN)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 6387977

Group type: EXPERIMENTAL
Intervention: Wound stimulation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Remote stimulation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Wound stimulation and remote stimulation
Number of subjects: 40
Study: 31663569

Group type: EXPERIMENTAL
Intervention: Yoghurt enriched with vitamins B1, B5 and B6 (VY)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional yoghurt (CY)
Number of subjects: 33
Study: 31340132

Group type: EXPERIMENTAL
Intervention: Barium sulfate with sodium bicarbonate granules
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Carbonated water
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Barium sulfate with carbonated water
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 42
Study: 28938876

Group type: EXPERIMENTAL
Intervention: Larval source management (LSM) and house improvement (HI) as additional interventions to standard malaria control strategies.
Number of subjects: 25000

Group type: COMPARATOR
Intervention: Standard malaria control strategies (LLINs and IRS).
Number of subjects: 25000
Study: 25150159

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 units · mL(‐1) (Gla‐300) at 0.4 units · kg(‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Insulin glargine 100 units · mL(‐1) (Gla‐100) at 0.4 units · kg(‐1)
Number of subjects: 30
Study: 24511720

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl 1 microg/kg
Number of subjects: 144

Group type: COMPARATOR
Intervention: Normal saline 1 ml/10 kg
Number of subjects: 144
Study: 21680653

Group type: EXPERIMENTAL
Intervention: Automated volumetry (ABV)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Manual volumetry
Number of subjects: 70
Study: 18566109

Group type: EXPERIMENTAL
Intervention: Higher tidal volume ventilation
Number of subjects: 676

Group type: COMPARATOR
Intervention: Lower tidal volume ventilation
Number of subjects: 676
Study: 16864830

Group type: EXPERIMENTAL
Intervention: Combined IV-intra-arterial thrombolysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: IV thrombolysis
Number of subjects: 0
Study: 12838218

Group type: EXPERIMENTAL
Intervention: 2 L of polyethylene glycol-electrolyte solution, one tablet of bisacodyl, and a minimally restricted diet on the day before colonoscopy, and then 1 L of the same solution on the day of colonoscopy (Group B)
Number of subjects: 187

Group type: COMPARATOR
Intervention: 3 L of polyethylene glycol-electrolyte solution with a liquid diet on the day before colonoscopy (Group A)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 187
Study: 10834779

Group type: EXPERIMENTAL
Intervention: PCEA with 0.1% bupivacaine + fentanyl (3 microg/mL) at 5 mL/h
Number of subjects: 40
Study: 9118706

Group type: EXPERIMENTAL
Intervention: BiPAP System 12/4
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: BiPAP System 8/4
Number of subjects: 33

Group type: COMPARATOR
Intervention: O2 via a face mask
Number of subjects: 33
Study: 8436747

Group type: EXPERIMENTAL
Intervention: Zofenopril (angiotensin-converting enzyme inhibitor)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 3017605

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg b.d.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31468364

Group type: EXPERIMENTAL
Intervention: Mandibular advancement (0% 'habitual bite', 25%, 50%, 75%, 100% of maximum mandibular advancement)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Responders to MAS therapy
Number of subjects: 17

Group type: COMPARATOR
Intervention: 0% mandibular advancement
Number of subjects: 17
Study: 30577862

Group type: EXPERIMENTAL
Intervention: Three-step physician-driven support during the dying and death process
Number of subjects: 900

Group type: COMPARATOR
Intervention: Standard of care practice
Number of subjects: 900
Study: 27840477

Group type: EXPERIMENTAL
Intervention: Kermanshahi family traditional massage
Number of subjects: 50

Group type: COMPARATOR
Intervention: Classic treatment (control)
Number of subjects: 50
Study: 25222185

Group type: EXPERIMENTAL
Intervention: Modafinil 100 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 22104366

Group type: EXPERIMENTAL
Intervention: Incredible Years BASIC parenting program
Number of subjects: 33
Study: 20825695

Group type: EXPERIMENTAL
Intervention: Personalized letters plus an educational booklet (Group A)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Personalized letters only (Group B)
Number of subjects: 150
Study: 18257180

Group type: EXPERIMENTAL
Intervention: Mild-warm moxibustion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medication (Mecobalamin tablets)
Number of subjects: 60
Study: 15927394

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/d
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg/d
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Duloxetine (all active treatment groups)
Number of subjects: 457

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 457
Study: 12593490

Group type: EXPERIMENTAL
Intervention: Sigvaris Traveno elastic stockings (12-18 mm Hg pressure at the ankle)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Sigvaris Traveno stockings (for flights lasting 11-12 hours)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Control group (no prophylaxis for flights lasting 11-12 hours)
Number of subjects: 211
Study: 10687907

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bone Scintigraphy
Number of subjects: 20
Study: 8813982

Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy
Number of subjects: 50446
Study: 1869009

Group type: EXPERIMENTAL
Intervention: Number of positive axillary lymph nodes (0-3 versus 4+)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Localisation of tumour relapse (local versus visceral metastasis)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Localisation of tumour relapse (local versus bone metastases)
Number of subjects: 145
Study: 6988748

Group type: EXPERIMENTAL
Intervention: Short-course group (24 patients) receiving 24 hours of cephalosporin prophylaxis
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Long-course group (25 patients) receiving 5 days of cephalosporin prophylaxis
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (31 patients) receiving no prophylactic antibiotics
Number of subjects: 80
Study: 31550091

Group type: EXPERIMENTAL
Intervention: Preoperative mental health status (measured by SF-36 mental health component)
Number of subjects: 677

Group type: COMPARATOR
Intervention: Age, obesity, back pain, awaiting another joint arthroplasty operation
Number of subjects: 677
Study: 29101130

Group type: EXPERIMENTAL
Intervention: Enhanced expectancy manipulation and enhanced empathy manipulation
Number of subjects: 128

Group type: COMPARATOR
Intervention: Standard expectancy manipulation and standard empathy manipulation
Number of subjects: 128
Study: 25581505

Group type: EXPERIMENTAL
Intervention: Participation in the study
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Motivators for continued participation
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Tight control treatment strategy
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Good treatment strategy
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Good medication
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Good half-term results
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Overall experience of participation
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Additional examinations during yearly visits
Number of subjects: 508
Study: 23674254

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Delayed enteral nutrition (DEN)
Number of subjects: 60
Study: 17095194

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Remission group
Number of subjects: 462

Group type: COMPARATOR
Intervention: Non-remission group
Number of subjects: 462
Study: 15473387

Group type: EXPERIMENTAL
Intervention: Intruded teeth
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control teeth
Number of subjects: 0

Group type: COMPARATOR
Intervention: Test and control teeth
Number of subjects: 0
Study: 11294404

Group type: EXPERIMENTAL
Intervention: Laparoscopic GBP
Number of subjects: 70

Group type: COMPARATOR
Intervention: Open GBP
Number of subjects: 70
Study: 9085316

Group type: EXPERIMENTAL
Intervention: Vancomycin 1000 mg infused during the last hour of hemodialysis with cellulose triacetate (CT) hemodialyzer
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Vancomycin 1000 mg infused during the last hour of hemodialysis with cellulose acetate (CA) hemodialyzer
Number of subjects: 8

Group type: COMPARATOR
Intervention: Vancomycin 1000 mg infused after dialysis was completed (control)
Number of subjects: 8
Study: 7506181

Group type: EXPERIMENTAL
Intervention: nimesulide
Number of subjects: 35

Group type: COMPARATOR
Intervention: paracetamol
Number of subjects: 35
Study: 3566858

Group type: COMPARATOR
Intervention: Fendiline hydrochloride 200 mg, 400 mg, 600 mg, 800 mg, 1000 mg, 1200 mg (single doses)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Fendiline hydrochloride 400 mg twice daily (initially), reduced to 200 mg twice daily after 5 days due to intolerability
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (3 subjects per dose level in the first study and 3 subjects in the second study)
Number of subjects: 27
Study: 30716528

Group type: EXPERIMENTAL
Intervention: Parent recorded ECGs (1290 newborns)
Number of subjects: 2582

Group type: COMPARATOR
Intervention: Staff recorded ECGs (1292 newborns)
Number of subjects: 2582
Study: 29631857

Group type: EXPERIMENTAL
Intervention: aIIV4
Number of subjects: 10612
Study: 27959613

Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole
Number of subjects: 666

Group type: COMPARATOR
Intervention: Placebo plus letrozole
Number of subjects: 666
Study: 25210629

Group type: EXPERIMENTAL
Intervention: Supportive care
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Acupressure (BL32 acupoint)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study: 22215022

Group type: EXPERIMENTAL
Intervention: Aerobic conditioning (group A)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Functional strength training (group B)
Number of subjects: 41
Study: 21178939

Group type: EXPERIMENTAL
Intervention: Supervised exercise program (12 weeks, aerobic training, strength, and flexibility exercises, 3 times/week)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Supervised exercise program
Number of subjects: 27
Study: 17950835

Group type: EXPERIMENTAL
Intervention: Endeavor zotarolimus‐eluting stent (ZES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Driver bare metal stent (BMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: First‐generation Cypher sirolimus‐eluting stent (SES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paclitaxel‐eluting stent (PES)
Number of subjects: 0
Study: 15766375

Group type: EXPERIMENTAL
Intervention: 0.12% CHX non-alcohol base with 0.05% cetyl pyridinium chloride (Cpc) mouthrinse (Perioaid), 15 ml, twice daily for 30 s
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.2% CHX alcohol base (Corsodyl), 10 ml, twice daily for 60 s
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.12% CHX non-alcohol base with 0.05% cetyl pyridinium chloride (Cpc) mouthrinse (Perioaid)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.2% CHX alcohol base (Corsodyl)
Number of subjects: 40
Study: 11982617

Group type: EXPERIMENTAL
Intervention: Daclizumab 1 mg/kg/dose every 14 d for five doses (Group I)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Daclizumab 2 mg/kg/dose every 14 d for two doses (Group II)
Number of subjects: 166

Group type: COMPARATOR
Intervention: No antibody induction (Group III)
Number of subjects: 166
Study: 10459562

Group type: EXPERIMENTAL
Intervention: Low-intensity aerobic training (50% estimated VO2max for 60 minutes, 2-4 times per week for 5 months)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no physical training)
Number of subjects: 20
Study: 7598117

Group type: EXPERIMENTAL
Intervention: Fecal occult blood screening intervention
Number of subjects: 15476

Group type: EXPERIMENTAL
Intervention: Diagnostic colorectal examination (negative results)
Number of subjects: 15476
Study: 2113567

Group type: EXPERIMENTAL
Intervention: Thyrotropin‐releasing hormone (TRH) (200 micrograms iv)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1‐desamino‐8‐D‐arginine vasopressin (DDAVP) (4 micrograms iv)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Apomorphine HCl (Apo) (0.5 mg sc)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: DDAVP plus Apo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 37871

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 25
Study: 31124887

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg i.v. dexamethasone
Number of subjects: 98

Group type: COMPARATOR
Intervention: 2 cm i.v. 0.9% saline (Control)
Number of subjects: 98
Study: 27978548

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (1000 IU)
Number of subjects: 2259

Group type: COMPARATOR
Intervention: Calcium supplementation (1200 mg elemental calcium)
Number of subjects: 2259
Study: 25874636

Group type: EXPERIMENTAL
Intervention: Three fatty fish meals per week
Number of subjects: 106

Group type: COMPARATOR
Intervention: Habitual fish consumption
Number of subjects: 106

Group type: COMPARATOR
Intervention: Maximum of one fish meal per week
Number of subjects: 106
Study: 23691925

Group type: EXPERIMENTAL
Intervention: Family group psychotherapy (FGP) - 8 monthly sessions
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no psychotherapy)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Family group psychotherapy (FGP)
Number of subjects: 17
Study: 21316980

Group type: EXPERIMENTAL
Intervention: Digital device for AL measurement (Drentech PALM)
Number of subjects: 49
Study: 18672332

Group type: EXPERIMENTAL
Intervention: Silicone gel
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 17355744

Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination of valsartan (160 mg) and simvastatin (40 mg)
Number of subjects: 18
Study: 15287311

Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Ketorolac 30 mg
Number of subjects: 64
Study: 11517998

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) injections into the calf muscles
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline injections (single blind control)
Number of subjects: 10
Study: 9605054

Group type: EXPERIMENTAL
Intervention: Initial shock of 1.5 J/kg based on body weight
Number of subjects: 39
Study: 8139380

Group type: EXPERIMENTAL
Intervention: IV scopolamine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 3262334

Group type: EXPERIMENTAL
Intervention: Low-dose heparin plus electric stimulation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Low-dose heparin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 48
Study: 29658856

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy (pemetrexed and a platinum-based drug)
Number of subjects: 616

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (pemetrexed and a platinum-based drug)
Number of subjects: 616